There were mixed results for Actelion's clazosentan in a trial for moderate to severe cerebral vasospasm. The drug hit its primary endpoint but failed to achieve a clinical benefit, a secondary endpoint.
Actelion's head of clinical development, Isaac Kobrin, said, "A full data analysis and consultation with clinical experts is essential to better understand the apparent disconnect in this study between the significant reduction in cerebral vasospasm and clinical outcome assessed by the endpoint chosen. This full data analysis will determine the future development path."
- here's the release on Actelion